Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913)
- Author:
Ho-Jin SHIN
1
;
Do-Young KIM
;
Kihyun KIM
;
Chang-Ki MIN
;
Je-Jung LEE
;
Yeung-Chul MUN
;
Won-Sik LEE
;
Sung-Nam LIM
;
Jin Seok KIM
;
Joon Ho MOON
;
Da Jung KIM
;
Soo-Mee BANG
;
Jong-Ho WON
;
Jae-Cheol JO
;
Young Il KOH
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2024;56(3):956-966
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Purpose:The role of allogeneic stem cell transplantation (alloSCT) in multiple myeloma (MM) treatment remains controversial. We conducted a retrospective, multicenter, nationwide study in Korea to evaluate the outcomes of alloSCT in Asian patients with MM.
Materials and Methods:Overall, 109 patients with MM who underwent alloSCT between 2003 and 2020 were included in this study. Data were collected from the Korean Multiple Myeloma Working Party Registry.
Results:The overall response rate and stringent complete response plus complete response (CR) rates were 67.0 and 46.8%, respectively, after alloSCT. At a median follow-up of 32.5 months, the 3-year probability of progression-free survival (PFS) and overall survival (OS) rates were 69.3% and 71.8%, respectively. The 3-year probabilities of OS rates in the upfront alloSCT, tandem auto-alloSCT, and later alloSCT groups were 75.0%, 88.9%, and 61.1%, respectively. Patients who achieved CR before or after alloSCT had significantly longer OS (89.8 vs. 18 months and 89.8 vs. 15.2 months, respectively). Even though patients who did not achieve CR prior to alloSCT, those who achieve CR after alloSCT had improved PFS and OS compared to those who had no achievement of CR both prior and after alloSCT. Patients who underwent alloSCT with 1-2 prior treatment lines had improved PFS (22.4 vs. 4.5 months) and OS (45.6 vs. 15.3 months) compared to those with three or more prior treatment lines.
Conclusion:AlloSCT may be a promising therapeutic option especially for younger, chemosensitive patients with earlier implementation from relapse.
